Last reviewed · How we verify
Evaluation of Two Cell-based Assays for Diagnosing MOG-IgG Associated Disorders
Anti-myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD) is a rare inflammatory autoimmune disease. In addition, since the international MOGAD group proposed live-cell based assays for MOGAD diagnosis in 2023, there are still no real-world cohort validation studies on this methodology. This study intends to establish a large sample cohort with multi-center and paired design. MOG-IgG detection based on live cells and fixed cells was performed on the study participants with high suspicion of MOGAD and the negative control population, to obtain the diagnostic performance parameters and consistency evaluation of the two methodologies, evaluate their clinical diagnostic value, and explore the best individual assay cutoffs for MOG-IgG detection suitable for the diagnosis of MOGAD in China.
Details
| Lead sponsor | Huashan Hospital |
|---|---|
| Status | RECRUITING |
| Enrolment | 240 |
| Start date | Mon Nov 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Dec 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders
Interventions
- CBA method of live cells and fixed cells
Countries
China